Navigation Links
Medivation Announces Participation in Upcoming Conferences
Date:5/13/2008

l of Dimebon in patients with mild-to-moderate Huntington's disease, and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
4. China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
5. Good Feet Announces New Arch Support Product Line for Children Ages 6 and Older
6. Samplify Systems Announces Availability of Compression for Computed Tomography; Integrated Slip-Ring Solution to be Jointly Developed with Schleifring und Apparatebau and Tokyo Electron Device Ltd.
7. Chiltern Announces New Expansion in Portugal
8. NutraCea Announces First Quarter 2008 Financial Results
9. Westaim announces 2008 first quarter results
10. China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
11. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...ough the number of jobs created in the medical fie...ed a different kind of slowdown: they laid off few... Seattle, WA (PRWEB) July 25, 2...dical field slowed in June overall, pharmaceutical...hat will be music to the ears of sales representat...
(Date:7/25/2008)...f Marketing Exclusivity Begins -, CORONA, Calif.,...uticals, Inc. (NYSE: WPI ), a leading specialty p...bsidiary has commenced commercial,shipment of its ... the 40mg,strength from its Davie, Florida manufac...atson has 180 days of marketing exclusivity for be...
(Date:7/25/2008)...5 /PRNewswire/ -- Sagent Pharmaceuticals, Inc.,a ...oday announced that it,has launched amiodarone HCl...ted for the treatment and prophylaxis of frequentl...ically unstable ventricular,tachycardia -- a poten...nt,s amiodarone HCl injection will be available im...
(Date:7/25/2008)...5 /PRNewswire/ -- AutoGenomics, Inc. today,announc...orm S-1 with the,Securities and Exchange Commissio... of shares of its common stock. The number of shar... expected to be offered by,AutoGenomics, Inc., and...en,determined., J.P. Morgan Securities Inc. is ac...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2
...vouch for the difficulty of capturing a clear pict...es, however, sometimes the motion is exactly what ...d the pathological protein mis-folding and assembl... a host of human disorders, including diabetes and...
...merican research, there is still hope for the couc...urch, director of the Laboratory of Preventive Med...ch Center at Louisiana State University, shows tha...d daily exercise dose, a substantial and immediate...
... the outrage over an insensitive caption for the p...lia, comes the news that a pre-schooler was found...al for unwanted babies. The drop-off was opened b...e southern city of Kumamoto to discourage abortion...
...g Administration (FDA) today approved Evicel Fibri...cally helps control oozing from small blood vesse...n effective means to stop oozing from small vessel...ring, compression or other standard techniques are...
Other Medicine News:Health News:Decoding Protein Structures Helps Illuminate Cause of Diabetes 2Health News:Spare Just Ten Minutes A Day For A Healthier Heart 2Health News:Three-year-old Abandoned in Box Meant for Unwanted Babies in Japan 2
(Date:7/24/2008)...eeds Oncology Patient Accrual, DENVER, July 24 /P...ent,Organization (RMO), has contracted with five l...h and site management services for their,clinical ...ategy. The new,trials include the following diseas...Metastatic Breast Cancer, Metastatic Sarcoma, Chro...
(Date:7/23/2008)...in July print edition of Clinical ...uly 23 /- A Roche Diagnostics-sponsor...o-B-type natriuretic peptide,(NT-proBNP) confirms ...cation in predicting the risk of cardiovascular ad...steroidal anti-inflammatory drugs of,the COX inhib...
(Date:7/23/2008).../ -- InCode BioPharmaceutics, Inc.,an emerging bi...al test,results demonstrating the utility of their...e rare chronic blood disorder paroxysmal nocturnal...e presented at the XXII,International Complement W..., The only treatment currently available for PNH ...
(Date:7/22/2008)...-- Nonin Medical, a leading innovator,of physiolog...has entered,the clinical testing phase with its br...aturation. Today,s most common application for thi...egional blood oxygenation,in the brain -- cerebral...an ongoing clinical study at the,Duke University M...
Breaking Medicine Technology:Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Advanced Energy Consortium will develop micro and nanosensors to boost energy production 2605 1Advanced Energy Consortium will develop micro and nanosensors to boost energy production 2605 2Pelosi Democrats Host Health Care Forum This Morning 9587 1Pelosi Democrats Host Health Care Forum This Morning 9587 2Pelosi Democrats Host Health Care Forum This Morning 9587 3Pelosi Democrats Host Health Care Forum This Morning 9587 4Wisconsin Physicians Service Insurance Corporation Files Suit Against Aurora Health Care and HealthEOS 9583 1Wisconsin Physicians Service Insurance Corporation Files Suit Against Aurora Health Care and HealthEOS 9583 2The Widener University Elder Pennsylvanian Survey Finds Pennsylvanias Baby Boomers Anticipate Working Longer Retiring Later to Help Offset Looming He 9579 1The Widener University Elder Pennsylvanian Survey Finds Pennsylvanias Baby Boomers Anticipate Working Longer Retiring Later to Help Offset Looming He 9579 2The Widener University Elder Pennsylvanian Survey Finds Pennsylvanias Baby Boomers Anticipate Working Longer Retiring Later to Help Offset Looming He 9579 3The Widener University Elder Pennsylvanian Survey Finds Pennsylvanias Baby Boomers Anticipate Working Longer Retiring Later to Help Offset Looming He 9579 4
...stCall/ -- Kosan,Biosciences Incorporated presente...KOS-1584/R1645, an epothilone under,co-development...vity and tolerability in patients with solid tumor...ts (13 of 41,evaluable) including activity in pati...ostate, head and neck and other cancers. Common,to...
... IL, June 04, 2007,/PRNewswire-FirstCall/ - Cardio...ellas Pharma US, Inc. ("Astellas") today,announced...nical,study, called ACT 2. The trial evaluated the...n of vernakalant hydrochloride,("vernakalant (iv)"...al fibrillation or atrial flutter between 24 hours...
Other Medicine Technology:Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 2Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 3Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 4Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6
...te Focus from Thermo Labsystems was designed speci...performance. Advanced features such as the new fa...n microvolumes help to define this as a new leader...le handle plate offers a custom fit for different ...
...igital offers improved ergonomics for today's exac...fied grippy finger rest and the large display wind...ipette Digitals also feature soft-touch tip ejecti....) and super blow-out for 0.2 - 50ul micro volume ...
...els cover the range from 2ul to 5000ul. Fills and...prevents inadvertent volume change. Novel hand gr...te is autoclavable at 121C(250F). To prevent corr...ble for one-handed operation. Auto or Normal trig...
...pettor is the #1 Pipettor for sub-microliter pipet...iability. Continuously adjustable. Features lPLUS,...ter. Easy interchangeable ejector buttons to fit l...ip ejector with three different lengths. Air-displ...
Medicine Products: